From the Guidelines
The dosing regimen for Mounjaro (tirzepatide) is 2.5 mg, 5 mg, or 10 mg once weekly, with a maximum dose of 15 mg once weekly.
Dosing Information
- The typical adult maintenance dose for tirzepatide is 5,10, or 15 mg once weekly 1.
- The medication is administered subcutaneously once weekly 1.
- The maximum approved dose is 15 mg once weekly, with a maximum appropriate dose of 15 mg 1.
Important Considerations
- Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist, and its use may be associated with gastrointestinal side effects, injection site reactions, and other potential safety concerns 1.
- The medication has a black box warning for the risk of thyroid C-cell tumors in rodents, although the human relevance is not determined 1.
- Females using oral contraceptives should be advised to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation 1.
From the FDA Drug Label
The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. The 2. 5 mg dosage is for treatment initiation and is not intended for glycemic control. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase the dosage in 2. 5 mg increments after at least 4 weeks on the current dose. The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.
The dosing regimen for Mounjaro (tirzepatide) 2.5 mg weekly is as follows:
- Initial dose: 2.5 mg injected subcutaneously once weekly for 4 weeks
- Dose escalation: Increase the dosage to 5 mg injected subcutaneously once weekly after 4 weeks
- Subsequent dose adjustments: Increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose if additional glycemic control is needed
- Maximum dose: 15 mg injected subcutaneously once weekly 2 2
From the Research
Dosing Regimen for Mounjaro (Tirzepatide) 2.5 mg Weekly
- The dosing regimen for Mounjaro (tirzepatide) 2.5 mg weekly is not explicitly stated in the provided studies as a standard or recommended dose for all patients.
- However, in one study 3, a patient with type 1 diabetes and obesity was started on tirzepatide 2.5 mg weekly and titrated to 7.5 mg weekly with 4-week dose titrations.
- Another study 4 mentions that patients with chronic kidney disease undergoing haemodialysis received weekly tirzepatide doses (2.5-7.5 mg) once a week.
- It is essential to note that the dosing regimen may vary depending on the patient's condition, response to treatment, and other factors, and should be determined by a healthcare professional.
Titration and Administration
- The studies suggest that tirzepatide can be administered once a week, with a starting dose of 2.5 mg and potential titration to higher doses (e.g., 7.5 mg) based on patient response and tolerance 3, 4.
- The administration of tirzepatide should be done under the guidance of a healthcare professional, taking into account the patient's individual needs and medical history.
Efficacy and Safety
- The studies demonstrate the efficacy and safety of tirzepatide in improving glycemic control, reducing body weight, and delaying progression to type 2 diabetes in patients with obesity and prediabetes 5.
- However, the studies also report potential side effects, such as nausea, vomiting, diarrhea, and constipation, which are common with GLP-1 receptor agonists 6, 7.